Literature DB >> 24816187

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Francois Moisan1, Edgar B Francisco1, Anamaria Brozovic1, George E Duran1, Yan C Wang1, Shalini Chaturvedi2, Shobha Seetharam2, Linda A Snyder2, Parul Doshi2, Branimir I Sikic3.   

Abstract

Ovarian cancer is associated with a leukocyte infiltrate and high levels of chemokines such as CCL2. We tested the hypothesis that CCL2 inhibition can enhance chemotherapy with carboplatin and paclitaxel. Elevated CCL2 expression was found in three non-MDR paclitaxel resistant ovarian cancer lines ES-2/TP, MES-OV/TP and OVCAR-3/TP, compared to parental cells. Mice xenografted with these cells were treated with the anti-human CCL2 antibody CNTO 888 and the anti-mouse MCP-1 antibody C1142, with and without paclitaxel or carboplatin. Our results show an additive effect of CCL2 blockade on the efficacy of paclitaxel and carboplatin. This therapeutic effect was largely due to inhibition of mouse stromal CCL2. We show that inhibition of CCL2 can enhance paclitaxel and carboplatin therapy of ovarian cancer.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CCL2; CCR2; Carboplatin; EMT; Paclitaxel; Resistance

Mesh：

Substances：

Year:  2014        PMID： 24816187      PMCID： PMC4801026          DOI： 10.1016/j.molonc.2014.03.016

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  24 in total

Review 1.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

2.  Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.

Authors:  Galina Obmolova; Alexey Teplyakov; Thomas J Malia; Tami L R Grygiel; Raymond Sweet; Linda A Snyder; Gary L Gilliland
Journal:  Mol Immunol       Date:  2012-04-07       Impact factor: 4.407

3.  Twist1 induces CCL2 and recruits macrophages to promote angiogenesis.

Authors:  Janine M Low-Marchelli; Veronica C Ardi; Edward A Vizcarra; Nico van Rooijen; James P Quigley; Jing Yang
Journal:  Cancer Res       Date:  2013-01-15       Impact factor: 12.701

Review 4.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

Review 5.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

6.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Authors:  Kenneth J Pienta; Jean-Pascal Machiels; Dirk Schrijvers; Boris Alekseev; Mikhail Shkolnik; Simon J Crabb; Susan Li; Shobha Seetharam; Thomas A Puchalski; Chris Takimoto; Yusri Elsayed; Fitzroy Dawkins; Johann S de Bono
Journal:  Invest New Drugs       Date:  2012-08-21       Impact factor: 3.850

7.  Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

Authors:  Gerald J Fetterly; Urvi Aras; Patricia D Meholick; Chris Takimoto; Shobha Seetharam; Thomas McIntosh; Johann S de Bono; Shahneen K Sandhu; Anthony Tolcher; Hugh M Davis; Honghui Zhou; Thomas A Puchalski
Journal:  J Clin Pharmacol       Date:  2013-07-23       Impact factor: 3.126

8.  Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Keiichi Kodama; Demi N Dang; Vu H Dang; Karine Breckpot; Kris Thielemans; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Clin Immunol       Date:  2008-03-12       Impact factor: 3.969

9.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Mamoru Yamashita; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

10.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Lashon L Day; Erin Sargent; Chris Neeley; Kirk Wojno; Linda A Snyder; Li Yan; Kenneth J Pienta
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701
View more
  37 in total

Review 1.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy.

Authors:  Jennifer L Guerriero
Journal:  Trends Mol Med       Date:  2018-04-11       Impact factor: 11.951

2.  Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Authors:  Jeanne M Quinn; Molly M Greenwade; Marguerite L Palisoul; Gregory Opara; Katina Massad; Lei Guo; Peinan Zhao; Hollie Beck-Noia; Ian S Hagemann; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2018-11-26       Impact factor: 6.261

Review 3.  Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.

Authors:  Umar Mehraj; Hina Qayoom; Manzoor A Mir
Journal:  Breast Cancer       Date:  2021-03-04       Impact factor: 4.239

4.  Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells.

Authors:  Xin Zhang; Jiandong Wang; Yali Fan; Ziyi Zhao; Sarah E Paraghamian; Gabrielle M Hawkins; Lindsey Buckingham; Jillian O'Donnell; Tianran Hao; Hongyan Suo; Yajie Yin; Wenchuan Sun; Weimin Kong; Delin Sun; Luyu Zhao; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-25       Impact factor: 4.322

5.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Authors:  Francois Moisan; Edgar B Francisco; Anamaria Brozovic; George E Duran; Yan C Wang; Shalini Chaturvedi; Shobha Seetharam; Linda A Snyder; Parul Doshi; Branimir I Sikic
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

Review 6.  Development and translation of novel therapeutics targeting tumor-associated macrophages.

Authors:  David Kosoff; Joshua M Lang
Journal:  Urol Oncol       Date:  2018-11-17       Impact factor: 3.498

Review 7.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

Review 8.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

9.  Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.

Authors:  Cheng-Ying Chu; Yi-Ching Lee; Cheng-Han Hsieh; Chi-Tai Yeh; Tsu-Yi Chao; Po-Hung Chen; I-Hsuan Lin; Tsung-Han Hsieh; Jing-Wen Shih; Chia-Hsiung Cheng; Che-Chang Chang; Ping-Sheng Lin; Yuan-Li Huang; Tsung-Ming Chen; Yun Yen; David K Ann; Hsing-Jien Kung
Journal:  Theranostics       Date:  2021-01-25       Impact factor: 11.556

Review 10.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.